# A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

> **NCT06830720** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 3250 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** ribociclib + AI ± LHRH
- **DRUG:** abemaciclib + ET ± LHRH
- **DRUG:** ET mono ± LHRH

## Key facts

- **NCT ID:** NCT06830720
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-20
- **Primary completion:** 2030-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 3250 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06830720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06830720, "A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06830720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*